Balaji Apb, Bhuvaneswari Srinivasan, Kumar D Nanda
Vanta Bioscience Limited, Gummidipoondi, Tamil Nadu, India; Ecoysus Life Science, Chennai, Tamil Nadu, India.
Ecoysus Life Science, Chennai, Tamil Nadu, India; Department of Biotechnology, Anna University, Chennai, Tamil Nadu, India.
Med Hypotheses. 2020 Nov;144:109976. doi: 10.1016/j.mehy.2020.109976. Epub 2020 Jun 7.
Several attempts to control the dreadfulness of SARS-CoV-2 are still underway. Based on the literature evidences we have speculated a prospective contemporary remedy, which was categorized into Specificity, Remedy, and a Conveyor. In which, pros and cons were discussed and inferred the possible alternatives. (a) Specificity: Implicit to express the ACE2 receptors in conveyor cells to deceive SARS-CoV-2 frompreponetargets. (b) Remedy: As depletion of pulmonary surfactants causes strong acute respiratory distress syndrome, we propose an entity of a cost-effective artificialsurfactantsystem as a remedy to pulmonary complications. (c) Conveyor: We propose red blood cells (RBCs) as a conveyor with embedded artificial surfactant and protruding ACE2 receptors for the target-specific delivery. Overall we postulate focused insights by employing a combinational contemporary strategy to steer towards a prospective direction on combating SARS-CoV-2.
目前仍在进行多项控制新冠病毒（SARS-CoV-2）严重性的尝试。基于文献证据，我们推测了一种前瞻性的当代疗法，该疗法分为特异性、治疗方法和载体三个部分。其中，讨论了利弊并推断了可能的替代方案。（a）特异性：在载体细胞中隐性表达血管紧张素转换酶2（ACE2）受体，以欺骗新冠病毒远离主要目标。（b）治疗方法：由于肺表面活性剂的消耗会导致严重的急性呼吸窘迫综合征，我们提出一种具有成本效益的人工表面活性剂系统作为肺部并发症的治疗方法。（c）载体：我们提出红细胞（RBCs）作为载体，其嵌入人工表面活性剂并突出ACE2受体以进行靶向特异性递送。总体而言，我们假设通过采用组合当代策略来获得有针对性的见解，以朝着抗击新冠病毒的前瞻性方向发展。
